Back to News
Market Impact: 0.35
TriSalus Gets FDA Clearance For TriNav Advance For Liver Embolization; Overnight Stock Up 17%
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
TriSalus Life Sciences received FDA 510(k) clearance for TriNav Advance, expanding its Pressure-Enabled Drug Delivery (PEDD) portfolio for liver embolization procedures. The clearance supports commercialization of the oncology-focused medical technology company's liver-directed treatment platform and is a positive catalyst for its product portfolio.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
TLSI0.78
More News
- Crude Oil Gains 1%; Cintas Earnings Top Views
- OpenAI’s agent hacked Australia’s Medicare website—the latest rogue AI incident that the company didn’t know about for months
- Meta announces new lightweight virtual reality glasses to one-up Apple’s Vision Pro
- US aviation sanctions disrupt Iran flights, push travellers overland
- Oil industry warns a diesel export ban will raise fuel prices as Trump weighs restrictions
- Australia says OpenAI agent hacked Medicare portal